Skip to main content
. 2020 Feb 28;11:136. doi: 10.3389/fphar.2020.00136

Figure 6.

Figure 6

Liraglutide promoted the proliferation of Scn1a knockout HT22 cell in a time-and-dose relationship. (A) RT-qPCR analysis of the Scn1a mRNA expression from HT22 and Scn1a KO cell (Student’s t-test, P < 0.001). (B) Representative western blotting showing SCN1A protein expression in the HT22 and Scn1a KO cell. (C) Summary graph of western blotting analysis demonstrating a significant reduction in the SCN1A protein in Scn1a KO as compared to HT22 cell (Student’s t-test, P < 0.001). (D) Morphological changes of Scn1a KO cell in different time treated with different concentrations of liraglutide. (E) Total number of cells in Scn1a KO cell line (Two-way ANOVA). (F) Cell proliferation by CCK-8 (Two-way ANOVA). The relative expression of SCN1A was normalized to reference controls Gapdh and β-actin in RT-qPCR and Western blotting, respectively. Data were presented as mean ± SD; *, **, *** represent P < 0.05, P < 0.01 and P < 0.001, respectively. All experiments were performed in triplicate. WT, Wild-type; KO, Scn1a Knockout in HT22 cell; Lira, Liraglutide.